Related Experiment Videos
[Ebastine vs terfenadine in allergic rhinitis]
L Terán Ortíz1, G Flores Sandoval, M Orea Solano
1Laboratorio de inmunologia e histocompatibilidad INER, SS.
Revista Alergia : Organo Oficial De La Sociedad Mexicana De Alergia E Inmunlogia
|July 1, 1993
Summary
Ebastine, a second-generation antihistamine, demonstrated superior efficacy in managing allergic rhinitis symptoms compared to terfenadine. This study highlights ebastine
Area of Science:
- Allergy and Immunology
- Pharmacology
- Clinical Medicine
Background:
- Allergic rhinitis significantly impacts quality of life.
- Second-generation antihistamines offer improved safety profiles over older agents.
- Evaluating novel antihistamines for effective rhinitis management is crucial.
Purpose of the Study:
- To compare the efficacy of ebastine versus terfenadine in treating allergic rhinitis.
- To assess symptom control in pediatric and adolescent patients.
- To evaluate the safety and tolerability of ebastine.
Main Methods:
- Prospective, comparative, randomized study.
- 40 patients with allergic rhinitis were treated with ebastine or terfenadine.
- Dosage of ebastine varied by age: 10 mg for 5-10 year olds, 20 mg for 11-15 year olds.
Main Results:
- Ebastine showed significantly greater efficacy in controlling rhinorrhea, nasal obstruction, sneezing, and itching from day seven (p < 0.05).
- Overall efficacy rates for ebastine (10/20 mg) were superior to terfenadine (p < 0.05).
- Ebastine exhibited good tolerability, with minor side effects (sleepiness, headache, nausea) in 1.5% of patients.
Conclusions:
- Ebastine is a more effective second-generation antihistamine for allergic rhinitis symptom control than terfenadine.
- Ebastine offers a favorable safety profile for pediatric and adolescent populations.
- The study supports ebastine as a valuable therapeutic option for allergic rhinitis.